<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786134</url>
  </required_header>
  <id_info>
    <org_study_id>2013P002186</org_study_id>
    <nct_id>NCT02786134</nct_id>
  </id_info>
  <brief_title>Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)</brief_title>
  <acronym>CIRT-CFR</acronym>
  <official_title>Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary flow reserve (CFR, calculated as the ratio of hyperemic over rest myocardial blood&#xD;
      flow) is emerging as a powerful quantitative prognostic imaging marker of clinical&#xD;
      cardiovascular risk. CFR provides a robust and reproducible clinical measure of the&#xD;
      integrated hemodynamic effects of epicardial coronary artery disease (CAD), diffuse&#xD;
      atherosclerosis, and microvascular dysfunction on myocardial tissue perfusion. Inflammation&#xD;
      is a key mediator of this constellation of abnormalities, affecting the entire coronary&#xD;
      vasculature, but no clinical trial to date has shown that directly reducing inflammation&#xD;
      lowers cardiovascular event rates. As such, the recently launched Cardiovascular Inflammation&#xD;
      Reduction Trial (CIRT) provides a unique opportunity for mechanistic investigation of the&#xD;
      impact of anti-inflammatory therapy on changes in CFR as a reflection of coronary vascular&#xD;
      dysfunction, which may precede clinical outcomes, particularly in patients at high-risk of&#xD;
      events. The investigators are ideally positioned to examine the impact of inflammation on&#xD;
      CFR, having extensive experience in both the quantitation of CFR using clinically-integrated&#xD;
      dynamic positron emission tomography (PET) and the ability to assess its association with&#xD;
      cardiovascular outcomes. The central hypothesis of this ancillary proposal, CIRT-CFR, is that&#xD;
      reducing systemic inflammation using low-dose methotrexate (LDM) will, compared to placebo,&#xD;
      quantitatively improve myocardial blood flow and coronary flow reserve as measured by PET&#xD;
      over one year, in stable CAD patients with type 2 diabetes or metabolic syndrome enrolled in&#xD;
      CIRT. In so doing, improvement in coronary vasoreactivity, endothelial function, and tissue&#xD;
      perfusion may have beneficial effects on myocardial mechanics, left ventricular deformation&#xD;
      and function and, ultimately, symptoms and prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization and double-blind study treatment period to either placebo or LDM (1:1) of&#xD;
      willing and eligible patients will occur at the end of the open label run-in phase per the&#xD;
      parent CIRT protocol, and will be stratified by time since the qualifying event (&lt; 6 or ≥ 6&#xD;
      months from the date of MI or most recent angiogram), type of event (MI or multivessel CAD),&#xD;
      presence of either type 2 DM or metabolic syndrome, and site, which will ensure balance in&#xD;
      the proposed study. Patients willing to participate in CIRT will be asked to enroll into the&#xD;
      sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent&#xD;
      CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After&#xD;
      giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline PET&#xD;
      scan along with echocardiography at any point between the parent CIRT post run-in visit&#xD;
      (Visit 3) and up to 4 weeks after randomization (Visit 4).&#xD;
&#xD;
      Imaging will be performed at the 3 imaging centers (BWH, OHI, and UAB). To minimize&#xD;
      participant and site burden, only a baseline and single follow-up imaging time point will be&#xD;
      pursued. Imaging tests (PET and echo) will be scheduled on the same day for patient&#xD;
      convenience if possible, and no more than one week apart. &quot;Baseline&quot; study visit imaging will&#xD;
      follow the open label run-in period of the parent trial to enhance long-term compliance and&#xD;
      eliminate risk of radiation exposure for any individuals with immediate intolerance to the&#xD;
      LDM study protocol. The imaging tests proposed are non-invasive, routinely performed, and&#xD;
      historically well tolerated by patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The CIRT-CFR study is a sub-study based off the main CIRT trial.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Global Myocardial Blood Flow in Response to Vasodilator</measure>
    <time_frame>12 months</time_frame>
    <description>Change (from baseline) in global coronary flow reserve in response to vasodilator as measured by PET imaging at baseline and at one year</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>low-dose methotrexate (LDM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <description>A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
    <arm_group_label>low-dose methotrexate (LDM)</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Echocardiogram</intervention_name>
    <description>An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
    <arm_group_label>low-dose methotrexate (LDM)</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years at screening;&#xD;
&#xD;
          2. Documented past history of MI OR past evidence of multivessel CAD by angiography,&#xD;
             completed any planned coronary revascularization associated with a qualifying event at&#xD;
             least 60 days prior to enrollment, and clinically stable for ≥60 days prior to&#xD;
             enrollment; qualifying prior MI must be documented either by hospital records,&#xD;
             evidence on current ECG of Q waves in 2 contiguous leads, and/or an imaging test&#xD;
             demonstrating wall motion abnormality or scar; qualifying evidence of multivessel CAD&#xD;
             by angiography must be documented by CAD in at least two major epicardial vessels&#xD;
             defined either as the presence of a stent, a coronary artery bypass graft, or an&#xD;
             angiographic lesion of 60% or greater (left main CAD that has been revascularized with&#xD;
             a stent or bypass graft will qualify as multivessel disease, as will the presence of a&#xD;
             50% or greater isolated left main stenosis);&#xD;
&#xD;
          3. History of type 2 DM or metabolic syndrome (meeting 2004 AHA/NHLBI definition*) at&#xD;
             time of study enrollment; *includes any 3 of the following 5 diagnostic criteria:&#xD;
             waist circumference ≥ 102 cm in men or 88 cm in women; triglycerides ≥ 150 mg/dl or on&#xD;
             drug treatment for elevated triglycerides; high-density lipoprotein cholesterol&#xD;
             (HDL-C)&lt; 40 mg/dL in men or &lt; 50 mg/dL in women or on drug treatment for reduced&#xD;
             HDL-C; systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg or&#xD;
             on drug treatment for hypertension; and elevated fasting glucose ≥ 100 mg/dL or on&#xD;
             drug treatment for elevated glucose.&#xD;
&#xD;
          4. Willingness to participate as evidenced by signing the CIRT and CIRT-CFR informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Prior history of chronic infectious disease, tuberculosis, or severe fungal disease;&#xD;
             chronic hepatitis B or C infection; renal insufficiency; interstitial pneumonitis,&#xD;
             bronchiectasis, or pulmonary fibrosis; known chronic pericardial effusion, pleural&#xD;
             effusion, or ascites; chronic liver disease; myeloproliferative disorders in the past&#xD;
             5 years; non-basal cell malignancy or treated lymphoproliferative disease within the&#xD;
             past 5 years; known HIV positive; life expectancy of &lt;3 years;&#xD;
&#xD;
          2. Chronic inflammatory condition such as lupus or rheumatoid arthritis, ulcerative&#xD;
             colitis or Crohn's disease&#xD;
&#xD;
          3. White blood cell count &lt;3,500/ul, hematocrit &lt; 32 percent, or platelet count &lt;&#xD;
             75,000/ul&#xD;
&#xD;
          4. Liver transaminase levels (AST or ALT) &gt;upper limit of normal (ULN) or albumin &lt; the&#xD;
             lower limit of normal (LLN);&#xD;
&#xD;
          5. Creatinine clearance &lt; 40 ml/min as estimated with the Cockroft-Gault equation;&#xD;
&#xD;
          6. History of alcohol abuse or unwillingness to limit alcohol consumption to less than 4&#xD;
             drinks per week&#xD;
&#xD;
          7. Women of child bearing potential, even if they are currently using contraception, and&#xD;
             women intending to breastfeed.&#xD;
&#xD;
          8. Men who plan to father children during the study period or who are unwilling to use&#xD;
             effective forms of contraception.&#xD;
&#xD;
          9. Requirement for use of drugs that alter folate metabolism&#xD;
             (trimethoprim/sulfamethoxazol) or reduce tubular excretion (probenecid) or known&#xD;
             allergies to antibiotics making avoidance of trimethoprim impossible;&#xD;
&#xD;
         10. Current indication for methotrexate therapy;&#xD;
&#xD;
         11. Chronic use of oral steroid therapy or other immunosuppressive or biologic response&#xD;
             modifiers (see Exclusionary Medication List in Manual of Operations). Eligible study&#xD;
             participants will be encouraged to have up to date pneumococcal and influenza&#xD;
             vaccinations as recommended based on their age and underlying medical conditions.&#xD;
&#xD;
         12. Chest X-ray evidence in the past 12 months of interstitial pneumonitis,&#xD;
             bronchiectasis, or pulmonary fibrosis. For participants who do not have a chest X-ray&#xD;
             in the prior 12 months, a chest X-ray will be obtained at baseline as part of the&#xD;
             study protocol.&#xD;
&#xD;
         13. New York Heart Association Class IV congestive heart failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <results_first_submitted>November 13, 2020</results_first_submitted>
  <results_first_submitted_qc>December 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2021</results_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Marcelo F. Di Carli, MD, FACC</investigator_full_name>
    <investigator_title>Chief of Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02786134/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low-Dose Methotrexate (LDM)</title>
          <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.&#xD;
PET scan: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.&#xD;
Echocardiogram: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.&#xD;
PET scan: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.&#xD;
Echocardiogram: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-dose Methotrexate (LDM)</title>
          <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.&#xD;
PET scan: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.&#xD;
Echocardiogram: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.&#xD;
PET scan: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.&#xD;
Echocardiogram: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="61" upper_limit="73"/>
                    <measurement group_id="B2" value="63" lower_limit="57" upper_limit="68"/>
                    <measurement group_id="B3" value="65" lower_limit="59" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Global Myocardial Blood Flow in Response to Vasodilator</title>
        <description>Change (from baseline) in global coronary flow reserve in response to vasodilator as measured by PET imaging at baseline and at one year</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-Dose Methotrexate (LDM)</title>
            <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.&#xD;
PET scan: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.&#xD;
Echocardiogram: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.&#xD;
PET scan: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.&#xD;
Echocardiogram: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Myocardial Blood Flow in Response to Vasodilator</title>
          <description>Change (from baseline) in global coronary flow reserve in response to vasodilator as measured by PET imaging at baseline and at one year</description>
          <units>percentage change in CFR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.192" upper_limit="0.288"/>
                    <measurement group_id="O2" value="-0.145" lower_limit="-0.429" upper_limit="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>The adverse definitions match those listed on clincaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low-Dose Methotrexate (LDM)</title>
          <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.&#xD;
PET scan: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.&#xD;
Echocardiogram: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.&#xD;
PET scan: A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.&#xD;
Echocardiogram: An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling at IV site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath during PET scan</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache during PET scan</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Chest Pain during PET scan</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Developed atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marcelo Di Carli</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-6290</phone>
      <email>mdicarli@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

